UPTAKE AND DIFFUSION OF PHARMACEUTICAL INNOVATIONS IN HEALTH SYSTEMS - Innovation in the Biopharmaceutical Industry - page 101

Carrin, G and P Hanvoravongchai (2003). Provider payments and patient charges as policy
tools for cost-containment: how successful are they in high-income countries? Human
Resources for Health , 1(1).
Chernew, M, AM Fendrick and RA Hirth (1997). Managed care and medical technology:
implications for cost growth. Health Affairs , 16(2), 196-206.
Cunningham, PJ (2002). Prescription drug access: not just a Medicare problem. Issue Brief
- Center for Studying Health System Change , 51, 1-4.
Cutler, DM and M McClellan (2001). Is technological change in medicine worth it? Health
Affairs , 20(5), 11-29.
Danzon, PM (1999). The Pharmaceutical Industry. The Wharton School — University of
Pennsylvania.
Danzon, PM and LW Chao (2000). Cross-national price differences for pharmaceuticals:
how large, and why? Journal of Health Economics , 19(2), 159-195.
Danzon, PM and M Furukuwa (2003). Prices and availability of pharmaceuticals evi-
dence from nine countries. Health Affairs , July-December(Suppl), Web Exclusives:
W3-521-36.
Danzon, PM and JD Ketcham (2003). Reference pricing of pharmaceuticals for medicare:
evidence from Germany, the Netherlands and New Zealand. NBER Working Papers,
# 10007.
Danzon, PM and MV Pauly (2002). Health insurance and the growth of pharmaceutical
expenditures. Journal of Law & Economics , 45, 587-613.
Danzon, PM, RY Wang and L Wang (2005). The impact of price regulation on the launch
delay of new drugs: evidence from twenty-five major markets in the 1990s. Health
Economics , 14, 269-292.
Darba, J (2003). Pharmaceutical expenditure in Spain: evolution and cost containment
measures during 1998-2001. European Journal of Health Economics , 4(3), 151-157.
Davis, M et al . (1999). Prescription drug coverage, utilization, and spending among Medi-
care beneficiaries. Health Affairs , 18(1), 231-243.
Desiraju, R, H Nair and P Chintagunta (2004). Diffusion of new pharmaceutical drugs in
developing and developed nations. International Journal of Research in Marketing ,
21(4), 341-357.
Dickson, M and H Redwood (1998). Pharmaceutical reference prices: how do they work in
practice? Pharmacoeconomics , 14(5), 471-479.
DiMasi, J, R Hansen and H Grabowski (2003). The price of innovation new estimates of
drug development costs. Journal of Health Economics , 22(2), 151-185.
Dor, A (2004). Does cost sharing affect compliance. NBER Working Paper # 10738.
Draborg, E et al . (2005). International comparison of the definition and the practical
application of health technology assessment. International Journal of Technology
Assessment in Health Care , 21(1), 89-95.
Dustan, HP et al . (1992). Report of the task force on the availability of cardiovascular
drugs to the medically indigent. Circulation , 85(2), 849-860.
Earl-Slater, A (1997). Regulating the price of the UK's drugs: second thoughts after the
government's first report. British Medical Journal , 314(7077), 365-368.